Indiana-based Eli Lilly and Company reported on February 3, 2022, it recently submitted a request for Emergency Use Authorization to the U.S. FDA for bebtelovimab, an investigational anti-SARS-CoV-2 Monoclonal Antibody (mAbs). Bebtelovimab, which neutralizes the SARS-CoV-2 spike glycoprotein receptor-binding domain-specific antibody, is being evaluated to treat mild-to-moderate COVID-19 in adults and pediatric patients 12 years of age and older. Lilly's recent financial disclosure says 'authentic virus analysis of bebtelovimab confirmed earlier pseudovirus findings, which demonstrated bebtelovimab neutralizes coronavirus variants of concern, including Omicron.' The U.S. NIH's OpenData Portal Therapeutic Activity Explorer separately confirmed bebtelovimab's effectiveness against Omicron as of February...